PL3103802T3 - Nowy związek pirolopirymidyny lub jego sól, kompozycja farmaceutyczna zawierająca go, szczególnie środek do zapobiegania i/lub leczenia guzów itp. w oparciu o działanie hamujące nae - Google Patents

Nowy związek pirolopirymidyny lub jego sól, kompozycja farmaceutyczna zawierająca go, szczególnie środek do zapobiegania i/lub leczenia guzów itp. w oparciu o działanie hamujące nae

Info

Publication number
PL3103802T3
PL3103802T3 PL15811341T PL15811341T PL3103802T3 PL 3103802 T3 PL3103802 T3 PL 3103802T3 PL 15811341 T PL15811341 T PL 15811341T PL 15811341 T PL15811341 T PL 15811341T PL 3103802 T3 PL3103802 T3 PL 3103802T3
Authority
PL
Poland
Prior art keywords
prevention
salt
treatment
pharmaceutical composition
composition containing
Prior art date
Application number
PL15811341T
Other languages
English (en)
Inventor
Takashi Mizutani
Chihoko Yoshimura
Hitomi Kondo
Makoto Kitade
Shuichi Ohkubo
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3103802T3 publication Critical patent/PL3103802T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL15811341T 2014-06-24 2015-06-24 Nowy związek pirolopirymidyny lub jego sól, kompozycja farmaceutyczna zawierająca go, szczególnie środek do zapobiegania i/lub leczenia guzów itp. w oparciu o działanie hamujące nae PL3103802T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (ja) 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤
EP15811341.5A EP3103802B1 (en) 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Publications (1)

Publication Number Publication Date
PL3103802T3 true PL3103802T3 (pl) 2018-02-28

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15811341T PL3103802T3 (pl) 2014-06-24 2015-06-24 Nowy związek pirolopirymidyny lub jego sól, kompozycja farmaceutyczna zawierająca go, szczególnie środek do zapobiegania i/lub leczenia guzów itp. w oparciu o działanie hamujące nae

Country Status (21)

Country Link
US (2) US9963456B2 (pl)
EP (1) EP3103802B1 (pl)
JP (1) JP6192741B2 (pl)
KR (1) KR101947289B1 (pl)
CN (1) CN106661031B (pl)
AU (1) AU2015281155B9 (pl)
BR (1) BR112016025835B1 (pl)
CA (1) CA2946833C (pl)
DK (1) DK3103802T3 (pl)
ES (1) ES2656772T3 (pl)
HU (1) HUE037266T2 (pl)
MX (1) MX2016015015A (pl)
MY (1) MY183327A (pl)
NO (1) NO3103802T3 (pl)
PH (1) PH12016502130A1 (pl)
PL (1) PL3103802T3 (pl)
PT (1) PT3103802T (pl)
RU (1) RU2658008C2 (pl)
SG (1) SG11201608441YA (pl)
TW (1) TWI605048B (pl)
WO (1) WO2015199136A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018089786A1 (en) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
AU2019301697A1 (en) * 2018-07-13 2021-01-07 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
WO2007067559A2 (en) 2005-12-06 2007-06-14 Regents Of The University Of Minnesota Antibacterial agents
HRP20120786T1 (hr) 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
JP2013541587A (ja) 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎｅｄｄ８活性化酵素阻害剤の投与
CN103298817A (zh) 2011-01-07 2013-09-11 利奥制药有限公司 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
WO2013016906A1 (zh) * 2011-07-29 2013-02-07 深圳光启高等理工研究院 人工复合材料和人工复合材料天线
AU2013210403B2 (en) * 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof

Also Published As

Publication number Publication date
KR20170016510A (ko) 2017-02-13
EP3103802B1 (en) 2017-11-08
MY183327A (en) 2021-02-18
CN106661031A (zh) 2017-05-10
US10174040B2 (en) 2019-01-08
EP3103802A1 (en) 2016-12-14
JPWO2015199136A1 (ja) 2017-04-27
AU2015281155A1 (en) 2016-11-03
CA2946833A1 (en) 2015-12-30
EP3103802A4 (en) 2017-03-08
JP6192741B2 (ja) 2017-09-06
NO3103802T3 (pl) 2018-04-07
US9963456B2 (en) 2018-05-08
RU2658008C2 (ru) 2018-06-19
HUE037266T2 (hu) 2018-08-28
PH12016502130B1 (en) 2016-12-19
MX2016015015A (es) 2017-02-27
ES2656772T3 (es) 2018-02-28
PH12016502130A1 (en) 2016-12-19
CN106661031B (zh) 2019-07-23
TW201625629A (zh) 2016-07-16
WO2015199136A1 (ja) 2015-12-30
BR112016025835B1 (pt) 2022-09-20
CA2946833C (en) 2019-03-05
KR101947289B1 (ko) 2019-02-12
BR112016025835A2 (pl) 2017-08-15
AU2015281155B9 (en) 2017-11-16
DK3103802T3 (en) 2017-12-11
RU2016149319A3 (pl) 2018-06-18
SG11201608441YA (en) 2016-11-29
AU2015281155B2 (en) 2017-07-13
US20170066772A1 (en) 2017-03-09
PT3103802T (pt) 2017-12-11
RU2016149319A (ru) 2018-06-18
TWI605048B (zh) 2017-11-11
US20180162864A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
SG11201608441YA (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
IL254722A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
PL3672954T3 (pl) Związki, ich sole i ich zastosowanie w leczeniu chorób
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
HK1243935A1 (zh) 有机化合物
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
IL263793A (en) Compounds and preparations for the treatment of cancer
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
EP3241551A4 (en) Pharmaceutical composition for treating cancer, containing lactate metal salt
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PL3236961T3 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
HK1243936A1 (zh) 有机化合物
EP3290051A4 (en) Pharmaceutical composition for treating and/or preventing cancer
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
IL252487B (en) Arylalkylamine compounds for use in the prevention or treatment of cancer
EP3267992A4 (en) Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases
EP3219323B8 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
HK1235391A1 (en) Inhibitors of creatine transport and uses thereof